I treat ACADIA Pharmaceuticals as an attractive long-term investment opportunity based firstly on the demographic trends in the U.S. as well as in the world and secondly on diseases progressing Y/Y for which the company is developing medications.
ACADIA is well prepared financially and has the infrastructure for its new medication with FDA approval upcoming. Its investors can expect to see the company’s sales rise substantially in the short-term and long-term.
About the company
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a U.S. based biopharmaceutical company. It is engaged in the development and production of innovative